Medtronic receives CE Mark for VitalFlow™ Transport Frame Air and Ground (AG) as accessory to the VitalFlow Extracorporeal Membrane Oxygenation (ECMO) System in Europe

Medtronic plc, a global leader in medical technology, today announced it has officially received CE (Conformité Européenne) Mark approval in Europe for its VitalFlow™ Transport Frame Air and Ground (AG) as an accessory to its VitalFlow Extracorporeal Membrane Oxygenation (ECMO) system. This milestone signals a significant leap forward in delivering seamless, critical support that is designed for inter-hospital transport, or the transfer of patients between two or more medical facilities. Previously, the VitalFlow Console and accessories for intrahospital use were approved in June 2025, redefining ECMO care across Europe with a configurable one-system solution, designed for simplicity and performance, configurable and upgradeable architecture.

The VitalFlow Transport Frame AG System, which will be officially launched at the EuroELSO Congress on May 6-9 in Dublin, provides a stable, protected, and robust way to transport the entire VitalFlow ECMO system. The frame has been rigorously tested and cleared for use in both ambulance and fixed aircrafts, including rotary and wing.

A Commitment to Patients
"When a patient is in critical condition and clinicians need to move quickly, every moment counts," said Pieter Kappetein, Ph.D., M.D., chief medical officer, Cardiac Surgery and Aortic, Medtronic. "By expanding access through transport, we're helping to support the care of critically ill patients."

As the only company serving the entire heart care team - from cardiac surgeons to perfusionists - Medtronic continues to be a leader in heart valves, surgical ablation, left atrial appendage management (LAAM), revascularization, perfusion, cannulation technologies and ECMO therapies. This comprehensive approach empowers clinicians to deliver holistic, lifetime care for their patients.

About ECMO
ECMO uses a pump and oxygenator outside of the body to take over the work of the heart and lungs to restore health and extend life to critically ill patients who might otherwise expire. ECMO is most often used for life-threatening heart or lung failure to allow the heart and/or lung to rest and heal. It is also used as a bridge option to heart or lung transplantation or to further treatment such as heart assist device or left ventricular assist device (LVAD).

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
María Trenzado
Communications
Medtronic Western Europe
[email protected]

Becky Dvorak
Communications
Medtronic
[email protected]

Ingrid Goldberg
Investor Relations
Medtronic
[email protected]